ImmunityBio, Inc. (NASDAQ: IBRX) reported Q1 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $16.5 million versus the consensus estimate of $16.86 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.